All In Biotech

BLA 761248 · Eli Lilly CO

Kisunla

Donanemab-Azbt · Injection

NovelBreakthrough therapyPriority review

CDER novel approval, Jul 2, 2024: To treat Alzheimer's disease

Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 2, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

18

8 Phase 3, 6 recruiting

FAERS reports

3,074

1,485 serious, 71 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: AMYLOID RELATED IMAGING ABNORMALITIES Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhages >1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with KISUNLA [see Warnings and Precautions ( 5.1...

What it is approved for

From the label in effect Dec 30, 2025.

KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. KISUNLA is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. ( 1 )

Mechanism: Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. Donanemab-azbt reduces amyloid beta plaques, as evaluated in Study 1 [see Clinical Studies ( 14 )] .

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 1, 2025 Supplement 4 · Efficacy · priority review LabelLetterMedication Guide
  • Jul 2, 2024 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
  • KISUNLA · DONANEMAB-AZBT 350MG/20ML(17.5MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Donanemab" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • amyloid related imaging abnormality-oedema/effusion503
  • amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits416
  • infusion related reaction390
  • headache276
  • flushing196
  • amyloid related imaging abnormalities181
  • nausea140
  • cerebral haemorrhage130
  • dizziness129
  • cerebral microhaemorrhage109
  • chills105
  • dyspnoea105

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202474
20251,440
20261,560

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kisunla (Donanemab-Azbt)

2024 spending

$17K

Beneficiaries

n/a

16 claims

Per beneficiary

n/a

$32.03 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$16,976

Part B: Kisunla (Donanemab-Azbt) · HCPCS J0175

2024 spending

$5.2M

Beneficiaries

1,299

2,832 claims

Per beneficiary

$4,039

2024 ASP limit $4.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$5,246,234

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 47 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.